DIAGNOSTICS AND THERAPY OF VASCULAR AND COMBINED MENTAL DEBILITY

Abstract

The article provides a scientifically grounded approach to pharmacotherapy of vascular and combined mental debility. The role and place of memantin, an uncompetitive low-affinity antagonist of NMDA-receptors in regulation of glutamate-dependent links of excitotoxicity in combined mental debilities. The effectiveness of memantin is proved for all stages and in various forms of mental debility, including combined mental debility, as well as compatibility with other drugs in combined therapy, a favourable safety profile and good drug tolerability.

Keywords

• combined mental debility
• complex antidement therapy
• memantin